Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Intravenous Iron in the Management of Drug-resistant Restless Legs syndromeI (IRON-RLS)

11 września 2026 zaktualizowane przez: University Hospital, Montpellier

Intravenous Iron in the Management of Drug-resistant Restless Legs Syndrome: a Randomized Controlled Delayed-start Trial. IRON-RLS

The pathophysiology of restless legs syndrome (RLS) is not well understood: it is thought to involve intracerebral iron deficiency and dopaminergic dysregulation.

This study aims to evaluate the use of intravenous ferric carboxymaltose in patients with restless legs syndrome (RLS).

This study plans to include individuals with RLS, who will be divided into two groups:

  • One group will receive intravenous iron immediately after the baseline polysomnography
  • The second group will receive intravenous iron 3 months after randomization. In total, participants will be followed for 6 months, during which time they will be required to complete questionnaires regularly, undergo blood draws, and have two polysomnography tests.

Przegląd badań

Typ studiów

Interwencyjne

Zapisy (Szacowany)

66

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły
  • Starszy dorosły

Akceptuje zdrowych ochotników

Nie

Opis

Inclusion Criteria:

  • Age ≥ 18 years;
  • Weight ≥ 50 kg;
  • Drug-resistant RLS;
  • Severe to very severe RLS (IRLSSG-Q score > 20), persistent or recurrent for more than one month;
  • Treatment with dopamine agonists without exceeding the recommended doses (ropinirole ≤ 2 mg/day, pramipexole ≤ 0.54 mg/day, rotigotine ≤ 3 mg/day);
  • Treatment with dopamine agonists and/or α2δ ligands and/or opioids that has been stable for at least 3 months;
  • In cases of sleep apnea syndrome, treatment with continuous positive airway pressure (CPAP);
  • Participants were required to be fluent in spoken and written French, be enrolled in a health insurance plan, agree to the automated processing of anonymized confidential data, and have provided written, informed consent for the study.

Exclusion Criteria:

  • Iron supplementation (oral or intravenous) within 3 months prior to enrollment and throughout the study period
  • Serum ferritin < 50 µg/L or > 300 µg/L;
  • Transferrin saturation < 20% or > 45%;
  • Hemochromatosis;
  • RLS augmentation syndrome ;
  • Treatment with neuroleptics or antidepressants;
  • Allergy to iron;
  • Severe infectious or inflammatory disease within the past 3 months;
  • RLS associated with chronic kidney disease, pregnancy, or a clinically significant neurological or psychiatric disorder;
  • Severe sleep apnea syndrome (AHI > 30/h) that is untreated, or in cases where treatment is refused or has failed;
  • Known allergy, inflammatory, or immune disorder;
  • History of severe asthma, eczema, or any other atopic allergy;
  • Pregnancy or breastfeeding;
  • Also excluded are patients participating in another research study, those deprived of their liberty by judicial or administrative order, those living in a medical facility, those subject to a legal protection order, or those from whom consent could not be obtained.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Immediate treatment
The treatment will be administered at at baseline (V1), immediately after the baseline polysomnography
administration of 1 g of CMF for 2 hours under medical monitoring
Administration of 1 g of CMF for 2 hours under medical monitoring
Randomization in the arm "Immediate treatment" or "Delayed-onset treatment"
Completion of questionnaires and scales: European Quality of Life 5 Dimensions (EQ-5D), Epworth Sleepiness Scale (ESS), Clinical Global Impression (CGI), Patient Global Impression (PGI), Beck Depression Inventory-II (BDI-II), Augmentation Severity Rating Scale (ASRS), International Restless Legs Study Group Severity Rating Scale (IRLSSG-Q), International Restless Legs Syndrome (IRLS), Insomnia Severity Index (ISI)
Lumbar puncture performed according to standard practice
During inclusion visit (Day 0) only for women of childbearing age
Aktywny komparator: Delayed-onset treatment
The treatment will be administered at 12 weeks
administration of 1 g of CMF for 2 hours under medical monitoring
Administration of 1 g of CMF for 2 hours under medical monitoring
Randomization in the arm "Immediate treatment" or "Delayed-onset treatment"
Completion of questionnaires and scales: European Quality of Life 5 Dimensions (EQ-5D), Epworth Sleepiness Scale (ESS), Clinical Global Impression (CGI), Patient Global Impression (PGI), Beck Depression Inventory-II (BDI-II), Augmentation Severity Rating Scale (ASRS), International Restless Legs Study Group Severity Rating Scale (IRLSSG-Q), International Restless Legs Syndrome (IRLS), Insomnia Severity Index (ISI)
Lumbar puncture performed according to standard practice
During inclusion visit (Day 0) only for women of childbearing age

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
IRLSSG-Q score
Ramy czasowe: From Day 0 to Week 12
IRLSSG-Q : International Restless Legs Study Group Severity Rating Scale allows for the quantification of the severity of restless legs syndrome
From Day 0 to Week 12

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Periodic Limb Movements during Sleep (PLMS) index
Ramy czasowe: From V1 (Day 0) to V5 (week 24)
The PLMS Index measures the average number of involuntary leg movements per hour of sleeping during polysomnography. 15 or more per hour: Considered abnormal for adults and may suggest a condition called Periodic Limb Movement Disorder (PLMD) if it disrupts your sleep.
From V1 (Day 0) to V5 (week 24)
Total sleep time
Ramy czasowe: From day 0 to week 24
Total sleep time measured in minutes during polysomnography.
From day 0 to week 24
Sleep latency
Ramy czasowe: From Day 0 to week 24
Length of time in minutes it takes to transition from full wakefulness to the lightest stage of sleep after the lights are turned off.
From Day 0 to week 24
Sleep time at stage 1-2 during polysomnography
Ramy czasowe: From Day 0 to week 24
Time spent in stage 1-2 sleep measured in hours and minutes during polysomnography
From Day 0 to week 24
Sleep time at stage 3 during polysomnography
Ramy czasowe: From Day 0 to week 24
Time spent in stage 3 sleep measured in hours and minutes during polysomnography
From Day 0 to week 24
Micro-awakenings index (MAI)
Ramy czasowe: From Day 0 to week 24
The Micro-awakenings index measures the number of brief awakenings that the person does not notice per hour of sleep.
From Day 0 to week 24
Apnea-hypopnea index (AHI)
Ramy czasowe: From Day 0 to week 24
The apnea-hypopnea index (AHI) measures the average number of interruptions or reductions in breathing per hour of sleep to assess the severity of sleep apnea.
From Day 0 to week 24
Average arterial oxygen saturation (SaO2)
Ramy czasowe: From Day 0 to Week 24
The unit of measurement for SaO2 is the percentage (%).
From Day 0 to Week 24
Oxygen desaturation index (IDO)
Ramy czasowe: From Day 0 to week 24
The oxygen desaturation index (IDO) measures the number of significant drops in blood oxygen levels per hour of sleep.
From Day 0 to week 24
Serum ferritin
Ramy czasowe: From Day 0 to week 24
From Day 0 to week 24
Transferrin saturation coefficient
Ramy czasowe: From Day 0 to Week 24
From Day 0 to Week 24
Epworth Sleepiness Scale (ESS)
Ramy czasowe: From Day 0 to Week 24
A measure of excessive daytime sleepiness that quantifies the impact of the condition on alertness throughout the day. Eight everyday situations are rated (for example, watching television, riding as a passenger in a car, sitting quietly in a public place). Each situation is scored from 0 to 3 based on the likelihood of falling asleep. Total score 0-24; a score of ≥10 suggests excessive sleepiness
From Day 0 to Week 24
European Quality of Life 5 Dimensions (EQ-5D)
Ramy czasowe: From Day 0 to Week 24
EQ-5D: this self-administered questionnaire assesses five dimensions (mobility, daily activities, self-care, pain/discomfort, anxiety/depression) as well as overall health status on a visual scale from 0 to 100
From Day 0 to Week 24
Clinical Global Impression (CGI)
Ramy czasowe: From Day 0 to Week 24
The clinician's overall assessment of the illness, including CGI-S (severity) and CGI-I (change). 7-point scale: CGI-S 1 = normal, 7 = extremely ill; CGI-I 1 = markedly improved, 7 = markedly worsened
From Day 0 to Week 24
Patient Global Impression (PGI)
Ramy czasowe: From Day 0 to Week 24
Patient's overall perception of the severity of their illness or change; a simple 7-point scale, self-reported. A high score is associated with patients perceiving their symptoms as severe
From Day 0 to Week 24
Beck Depression Inventory-II (BDI-II)
Ramy czasowe: From Day 0 to Week 24
BDI-II: a self-administered questionnaire consisting of 21 items that assess the severity of depressive symptoms over the past two weeks; score range: 0-63; thresholds: 0-13 (mild), 14-19 (moderate), 20-28 (severe), ≥29 (severe)
From Day 0 to Week 24
Augmentation Severity Rating Scale (ASRS)
Ramy czasowe: From Day 0 to Week 24
A 7-item self-administered questionnaire used to quantify the severity of the augmentation syndrome in patients treated with dopamine agonists. It assesses the worsening or early onset of RLS symptoms and their impact on sleep and daily activities
From Day 0 to Week 24
Insomnia Severity Index (ISI)
Ramy czasowe: From Day 0 to week 24
To assess the severity of the patient's insomnia, taking into account both the quantity and quality of sleep, as well as its impact on daily functioning (fatigue, concentration, mood). A 7-item self-report questionnaire scored from 0 to 4, with a total score of 0-28; 0-7 indicates no insomnia, 8-14 mild, 15-21 moderate, and 22-28 severe insomnia
From Day 0 to week 24

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 października 2026

Zakończenie podstawowe (Szacowany)

1 kwietnia 2029

Ukończenie studiów (Szacowany)

1 października 2030

Daty rejestracji na studia

Pierwszy przesłany

28 sierpnia 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

11 września 2026

Pierwszy wysłany (Rzeczywisty)

16 września 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

16 września 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

11 września 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj